Toll Free: 1-888-928-9744

Grass Pollen Allergy - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 59 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Grass Pollen Allergy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Grass Pollen Allergy - Pipeline Review, H1 2016', provides an overview of the Grass Pollen Allergy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy
- The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects
- The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Grass Pollen Allergy Overview 7 Therapeutics Development 8 Pipeline Products for Grass Pollen Allergy - Overview 8 Grass Pollen Allergy - Therapeutics under Development by Companies 9 Grass Pollen Allergy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Grass Pollen Allergy - Products under Development by Companies 13 Grass Pollen Allergy - Companies Involved in Therapeutics Development 14 ALK-Abello A/S 14 Allergy Therapeutics Plc 15 Anergis SA 16 Biomay AG 17 Circassia Pharmaceuticals Plc 18 HAL Allergy BV 19 Roxall Medizin GmbH 20 Shionogi & Co., Ltd. 21 Grass Pollen Allergy - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 AllerG - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Allergen for Grass Allergy - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 asapiprant - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BM-32 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 clustoid wiesenlieschgras - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Pollinex Quattro Grass - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Grass Pollen Allergy - Recent Pipeline Updates 43 Grass Pollen Allergy - Dormant Projects 50 Grass Pollen Allergy - Product Development Milestones 51 Featured News & Press Releases 51 Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL 51 Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children 51 Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference. 52 Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 53 Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 54 Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 54 Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 55 Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 55 Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 56 Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Grass Pollen Allergy, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2016 14 Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2016 15 Grass Pollen Allergy - Pipeline by Anergis SA, H1 2016 16 Grass Pollen Allergy - Pipeline by Biomay AG, H1 2016 17 Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 18 Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2016 19 Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H1 2016 20 Grass Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H1 2016 21 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Stage and Target, H1 2016 24 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 Grass Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2016 43 Grass Pollen Allergy - Dormant Projects, H1 2016 50


List of Figures
Number of Products under Development for Grass Pollen Allergy, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Assessment by Monotherapy Products, H1 2016 22 Number of Products by Targets, H1 2016 23 Number of Products by Stage and Targets, H1 2016 23 Number of Products by Routes of Administration, H1 2016 26 Number of Products by Stage and Routes of Administration, H1 2016 26 Number of Products by Molecule Types, H1 2016 28 Number of Products by Stage and Molecule Types, H1 2016 28

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to driv

Read More...

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify